Abstracts tagged "gout"

Abstract Number: L08 • ACR Convergence 2020
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Thomas MacDonald¹, Isla Mackenzie¹, George Nuki² and Ian Ford³, ¹University of Dundee, Dundee, Scotland, United Kingdom, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
Abstract Number: 0652 • ACR Convergence 2020
Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout
Ruth Topless¹, Tony Merriman¹, Siamak Noorbaloochi² and Jasvinder Singh³, ¹University of Otago, Dunedin, New Zealand, ²University of Minnesota, Minneapolis, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Few studies, if any, have found association of the biochemical cause of gout (high serum urate) with functional limitation and health-related quality of life…
Abstract Number: 0672 • ACR Convergence 2020
Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares
Natalie McCormick¹, Chio Yokose¹, Clara Chen², Tuhina Neogi³, David Hunter⁴, Hyon Choi⁵ and Yuqing Zhang⁶, ¹Massachusetts General Hospital, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston
Background/Purpose: Cross-sectional radiologic evidence suggests monosodium urate crystal deposition among gout patients is a symmetrical phenomenon,1 but no study has examined the longitudinal patterns in…
Abstract Number: 0691 • ACR Convergence 2020
Denosumab Did Not Improve Computerized Tomography Erosion Scores When Added to Intensive Urate-Lowering Therapy in Gout: Results from a Pilot Study
Angelo Gaffo¹, Kenneth Saag², Anthony Doyle³, Joshua Melnick⁴, Anne Horne⁵, Jeffrey Foster¹, Amy Mudano¹, Stephanie Biggers¹, David Redden¹ and Nicola Dalbeth⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ³University of Auckland, Grafton, Auckland, New Zealand, ⁴University of Alabama at Birmingham (UAB), Vestavia Hills, AL, ⁵The University of Auckland, Auckland, New Zealand, ⁶University of Auckland, Auckland, New Zealand
Background/Purpose: Bone erosion is a common complication of tophaceous gout. Disordered osteoclast activity has been implicated in the pathogenesis of gouty bone erosion. We sought…
Abstract Number: 0653 • ACR Convergence 2020
Nutrient Content of Gout Flare Trigger Foods
Tanya Major¹, Ruth Topless¹, Elsa Sanchez-Lopez², Jennie Harré Hindmarsh³, Lisa Stamp⁴, Nicola Dalbeth⁵, Monica Guma⁶, Robert Terkeltaub⁷ and Tony Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²University of California San Diego, San Diego, CA, ³Ngāti Porou Hauora, Te Puia Springs, New Zealand, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of California San Diego, La Jolla, CA, ⁷VA/UCSD, San Diego, CA
Background/Purpose: A wide variety of foods are reported by patients to be triggers of gout flares. Some of these foods have been associated with serum…
Abstract Number: 0673 • ACR Convergence 2020
Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure
Brian LaMoreaux¹, Megan Francis-Sedlak¹, Scott Neville² and Robert Holt¹, ¹Horizon Therapeutics plc, Lake Forest, IL, ²Foot and Ankle Center, Mooresville, IN
Background/Purpose: Gout can cause uric acid deposition in joints, soft tissues, and organs (1) and is associated with heart disease, kidney disease, hypertension, hyperlipidemia, diabetes,…
Abstract Number: 0950 • ACR Convergence 2020
The Association Between Gout and Cardiovascular Disease Outcomes: Assessment and Recalibration of Individual-level Primary Prevention Risk Prediction Equations in Approximately 450,000 New Zealanders
Ken Cai¹, Billy Wu², Nicola Dalbeth², Rod Jackson² and Katrina Poppe², ¹University of Auckland, Sydney, New South Wales, Australia, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Some studies have reported that gout is an independent risk factor for cardiovascular disease (CVD). Individual-level cardiovascular risk prediction equations have been developed and…
Abstract Number: 0654 • ACR Convergence 2020
The Effects of Dietary Macronutrients on Serum Urate: A Secondary Analysis of the OmniHeart Trial
Matthew Belanger¹, Christina Wee¹, Kenneth Mukamal¹, Edgar Miller², Frank Sacks³, Lawrence Appel², Robert Shmerling⁴, Hyon Choi⁵ and Stephen Juraschek¹, ¹Beth Israel Deaconess Medical Center/Harvard Medical School, Division of General Medicine, Boston, MA, ²Johns Hopkins University, School of Medicine, Department of Medicine, Division of General Internal Medicine, Baltimore, MD, ³Harvard T. H. Chan School of Public Health, Department of Nutrition, Boston, MA, ⁴Beth Israel Deaconess Medical Center/Harvard Medical School, Division of Rheumatology, Mashpee, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Diet is a significant determinant of hyperuricemia and risk for gout. Dietary recommendations to prevent gout emphasize reducing purine intake; however, low-purine diets are…
Abstract Number: 0674 • ACR Convergence 2020
Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan
Ruriko Koto¹, Akihiro Nakajima¹, Hideki Horiuchi¹ and Hisashi Yamanaka², ¹Teijin Pharma Limited, Tokyo, Japan, ²Sanno Medical Center, Tokyo, Japan
Background/Purpose: Japanese guidelines for managing gout and hyperuricemia recommend the initiation of urate-lowering therapy (ULT) to prevent gouty arthritis in subjects having asymptomatic hyperuricemia with…
Abstract Number: 0951 • ACR Convergence 2020
The Comparative Effect of Exposure to Various Risk Factors on the Risk of Hyperuricaemia: Diet Has a Weak Causal Effect
Ruth Topless¹, Tanya Major¹, Jose Florez², Joel Hirschhorn³, Murray Cadzow¹, Nicola Dalbeth⁴, Lisa Stamp⁵, Phillip Wilcox¹, Richard Reynolds⁶, Joanne Cole² and Tony Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²Massachusetts General Hospital, Boston, ³Harvard Medical School, Boston, ⁴University of Auckland, Auckland, New Zealand, ⁵University of Otago Christchurch, Christchurch, New Zealand, ⁶University of Alabama Birmingham, Birmingham
Background/Purpose: Prevention of hyperuricaemia (HU) is critical to the prevention of gout. Therefore, understanding the causal relationships and relative contributions of various risk factors to…
Abstract Number: 0655 • ACR Convergence 2020
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial
Kristian Zobbe¹, Robin Christensen², Sabrina Mai Nielsen³, Lisa Stamp⁴, Marius Henriksen⁵, Anders Føhrby Overgaard⁶, Lene Dreyer⁷, Filip Krag Knop⁸, Jasvinder Singh⁹, Michael Doherty¹⁰, Pascal Richette¹¹, Arne Astrup¹², Karen Ellegaard¹, Else Marie Bartels¹³, Mikael Boesen¹⁴, Henrik Rindel Gudbergsen¹⁵, Henning Bliddal¹⁵ and Lars Erik Kristensen¹⁶, ¹The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, Denmark, ²Musculoskeletal Statistics Unit, The Parker Institute/Odense University Hospital, Copenhagen F, Denmark, ³The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Frederiksberg, Denmark, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, ⁶The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Sorø, ⁷Department of Rheumatology, Aalborg UnIversity Hospital, Aalborg, Denmark, ⁸Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, Copenhagen, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham UK, Nottingham, United Kingdom, ¹¹Department of Rheumatology, Lariboisière Hospital, Paris, France, ¹²Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark, ¹³Department of Neurology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Frederiksberg, Denmark, Copenhagen, Denmark, ¹⁴Department of Radiology Copenhagen University hospital Bispebjerg and Frederiksberg; The Parker Institute, Copenhagen, Denmark, ¹⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Frederiksberg, Denmark, ¹⁶The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Despite scarce evidence regarding the effects of weight loss in gout1, international guidelines recommend dietary advice and weight loss as a core management strategy…
Abstract Number: 0676 • ACR Convergence 2020
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
Joshua Gavin¹, Yashswee KC², Evan Dombrosky³, Nehal Shah⁴ and Youssef Roman⁴, ¹Virginia Commonwealth University School of Medicine, Richmond, ²Virginia Commonwealth University School of Medicine, Henrico, VA, ³Virginia Commonwealth University School of Medicine, Glen Allen, VA, ⁴Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…
Abstract Number: 0952 • ACR Convergence 2020
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Puja Khanna¹, Dinesh Khanna¹, Gary Cutter², Jeffrey Foster², Joshua Melnick³, Sara Jaafar¹, Stephanie Biggers², AKM Rahman², Hui-Chen Kuo², Michelle Feese² and Kenneth Saag⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham (UAB), Vestavia Hills, AL, ⁴University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…
Abstract Number: 0656 • ACR Convergence 2020
A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis
Philip Robinson¹, Nicola Dalbeth², Chris Frampton³, Tony Merriman³, Amanda Phipps-Green³ and Peter Donovan⁴, ¹University of Queensland, Herston, Queensland, Australia, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴Royal Brisbane & Women's Hospital, HERSTON, Queensland, Australia
Background/Purpose: Intake of sugar is associated with increased incident gout. Sugar taxes have been effective at reducing the intake of sugar in several jurisdictions. We…
Abstract Number: 0677 • ACR Convergence 2020
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
John Botson¹, Paul Peloso², Katie Obermeyer³, Brian LaMoreaux³, Lin Zhao³, Michael Weinblatt⁴ and Jeff Peterson⁵, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²Horizon Therapeutics plc, Gurnee, IL, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Western Washington Medical Group Arthritis Clinic, Bothell, WA
Background/Purpose: Consistent, though limited, published data suggests that methotrexate (MTX) improves treatment response in patients treated with pegloticase for uncontrolled (refractory) gout. Recent case series1-3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].